The Food and Drug Administration on Friday authorized the first over-the-counter home diagnostic capable of distinguishing influenza A, influenza B and COVID-19 from a single nasal sample, giving consumers a way to identify three major respiratory viruses without first visiting a clinic or laboratory.
The agency’s authorization announcement said the Lucira COVID-19 & Flu Home Test is intended for people with symptoms consistent with a respiratory infection. Individuals age 14 and older may collect their own anterior nasal sample, while an adult may collect a sample from a child age 2 or older. The single-use molecular test produces separate results for SARS-CoV-2, influenza A and influenza B in approximately 30 minutes.
One sample, three respiratory-virus results
The practical value is straightforward: fever, cough, fatigue and other respiratory symptoms can look similar across influenza and COVID-19, but the diseases have different treatment and isolation considerations. Until now, consumers could buy numerous home COVID-19 tests, but influenza testing generally required a health-care setting or laboratory process. A contemporaneous Washington Post report described the authorization as the first combination flu-coronavirus test that can be completed entirely at home.
FDA reported strong but not perfect performance in symptomatic participants. The test correctly identified 99.3% of negative and 90% of positive influenza A samples. For COVID-19, it identified 100% of negative and 88.3% of positive samples. It identified 99.9% of negative influenza B samples, but too little influenza B was circulating during the clinical study to generate enough naturally positive cases, so the agency required additional real-world data collection.
An Axios report published Friday noted that no prescription is required. That matters because the usefulness of a respiratory test depends heavily on timing. Influenza antivirals work best when started early, while COVID-19 treatment decisions for higher-risk patients also depend on prompt diagnosis and clinical evaluation.
Molecular testing moves further into the home
Lucira’s device uses molecular amplification rather than the lateral-flow antigen format familiar from many rapid COVID-19 tests. The company had previously received FDA authorization for a home molecular COVID-19 product; the agency’s 2020 authorization of Lucira’s COVID-19 All-In-One Test Kit marked the first prescription molecular test that could be fully self-administered at home.
The new combination product extends that model to influenza. A same-day Pharmacy Times account highlighted FDA’s warning that negative results do not always exclude infection and may require confirmatory molecular testing when the result would change clinical management. The agency also advised users to report results to health-care providers, both for appropriate care and public-health reporting.
That limitation is important because a consumer diagnostic does not replace clinical judgment. False negatives can occur when viral concentrations are low, sampling is inadequate or the timing of testing does not align with the course of infection. Likewise, a positive result may establish which virus was detected but does not by itself determine whether an antiviral prescription is appropriate, particularly for patients with drug interactions, underlying conditions or other risk factors.
A respiratory season reshaped by home testing
The authorization arrives after a winter in which influenza, COVID-19 and respiratory syncytial virus circulated simultaneously, putting pressure on pediatric hospitals and outpatient practices. The pandemic normalized home infectious-disease testing on a scale that did not exist before 2020. The Lucira authorization suggests that the home-testing market may now expand from single-pathogen COVID products toward multiplex diagnostics that answer the more clinically useful question: which respiratory virus is causing the symptoms?
The FDA maintains a broader EUA record showing the evolution of Lucira’s tests from earlier COVID-only products to combination coronavirus-influenza testing. The agency’s emergency-use pathway has allowed diagnostic manufacturers to introduce products more quickly during the public-health emergency, while imposing conditions on labeling, performance monitoring and continuing data collection.
The new authorization also comes with an unusual commercial complication. Lucira filed for Chapter 11 bankruptcy protection on Wednesday, two days before FDA authorized the home combination test. A contemporaneous Bloomberg Law report said the company listed approximately $146 million in assets and $85 million in liabilities and planned to continue operating while pursuing a sale. The financial filing creates uncertainty about how quickly the newly authorized product can reach broad retail distribution.
Access will determine the public-health impact
For clinicians and patients, the authorization is significant because it reduces the distance between symptoms and pathogen identification. A person who develops fever and cough can potentially obtain three molecular results at home within half an hour, then contact a clinician with more useful information. That could make treatment more targeted and reduce unnecessary antibiotic use when a viral infection is identified.
But the product’s real-world value will depend on price, manufacturing capacity, retail availability and whether consumers understand the need for follow-up when symptoms and results do not align. A Friday report summarized the core advantage: the same self-collected swab can distinguish flu from COVID-19 at home rather than forcing consumers to infer the cause from overlapping symptoms.
The FDA has therefore cleared an important technical threshold, but authorization is only the first step. If the product becomes widely available despite Lucira’s bankruptcy proceedings, it could establish a new category of consumer diagnostics in which home testing moves beyond a single pandemic virus and becomes a routine front end to respiratory care.
